← All Haemonetics CORP filings

Haemonetics CORP Form 4 insider transactions

NYSE
HAE
Haemonetics CORP
Form 4: Haemonetics EVP, Chief Technology Officer Anila Lingamneni Reports Stock Sale
Anila Lingamneni, EVP and Chief Technology Officer of Haemonetics Corp, reported selling 2,305 shares of common stock at $95 per share on May 6, 2024, under a pre-existing 10b5-1 trading plan.
NYSE
HAE
Haemonetics CORP
Form 4: Haemonetics EVP, Chief Financial Officer James D'Arecca Reports Changes in Beneficial Ownership
James D'Arecca, EVP and Chief Financial Officer of Haemonetics Corp, reports a transaction involving the withholding of shares for tax obligations related to vesting restricted stock units.
NYSE
HAE
Haemonetics CORP
Form 4: Haemonetics Corp Executive Anila Lingamneni Reports Stock Transaction
Anila Lingamneni, EVP and Chief Technology Officer of Haemonetics Corp, reports disposition of shares to cover tax obligations related to vesting restricted stock units.
NYSE
HAE
Haemonetics CORP
Form 4: Haemonetics Corp CEO Christopher Simon Reports Gift Transfer of Common Stock
Christopher Simon, President & CEO of Haemonetics Corp, reported a gift transfer of 38,900 shares of common stock to the Simon Family 2020 Irrevocable Trust on March 11, 2024.